Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (17368)	12/18/2002 11:56:30 AM
From: tuck	Respond to of 57110

Also watching IGEN hitting support at $40.50. And even ABI. I had this as a successful paper short and recently covered. Lehman may be right in that it got unjustly punished on WAT's lowered guidance. The big question is how much WAT's problem reflects weakness in the mass spec market. A good chunk of WAT's weakness was in the HPLC market to which ABI has no exposure. Since ABI was down only half as much on percentage basis, it would seem the market understood the exposure issue. Fine, but there are signs that a) the mass spec market is doing OK, and b) that there is some overlap in the two companies' mass spec product lines, and that ABI has been taking share. ABI a trading buy in the middle $17s, methinks. Anybody got a TA opinion on TELK? Cheers, Tuck